For most of the past two years, Alnylam Pharmaceuticals has been the biggest drug developer in Massachusetts (by market cap) that doesn’t yet have an approved product on the market. And while expectations are high for its potential amyloidosis drug, which will most likely be the first to gain approval in as soon as two years, much of the Cambridge-based biotech firm’s $8.8 billion in market value is tied up in the other many other drugs in its pipeline.
